Last week at the Beyond Sequencing Conference in San Francisco, almost 100 scientists packed the room to hear Sandeep Sanga, Ph.D. and CLC bio scientist Cecilie Boysen, Ph.D. present on “Integrated NGS Analysis Enables Rapid Biological Interpretation from Raw Reads: A Case Study on Prostate Cancer RNA-Seq Data.”
The June 21 presentation showed how IPA and the CLC Genomics Workbench were used together to analyze and identify insights from a publicly available prostate cancer RNA-Seq dataset. The talk highlighted how high-resolution analysis of altered expression of genes can help pinpoint specific pathways and processes activated in growing tumors. Ingenuity and CLC bio have a NGS data integration partnership where scientists can upload their CLC bio datasets into IPA.
Ingenuity and CLC bio also presented a poster based on the same case study, which spotlights how to deduct novel insights into the mechanisms of prostate adenocarcinoma by leveraging NGS data (in particular, human transcriptome data), for in silico data analysis and interpretation.
The following day on June 22, Ingenuity participated in a roundtable discussion on “The Cancer Genome and Tomorrow’s Health Care”, led by Mao Mao, M.D., Ph.D., from Pfizer’s Global Research and Development Oncology group. Dr. Mao also talked about how he utilized IPA for the identification of cancer driver variants in his talk entitled “Cancer Genome Sequencing for Drug Development.”
If you could not attend Beyond Sequencing but would like to learn more about how you can use IPA for NGS, register to attend a live webinar based on this same case study on our website or check out the pre-recorded version. See more photos from this event.
Click here to go to the Ingenuity.com home page.